Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 5/20 | 0.46 |
| ▸ | COMT | P21964 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669509 | 0.88 | FTO (0.43) | FTOCOMTEGFRCYP2C9 | |
| SCHEMBL32669560 | 0.86 | FTO (0.64) | FTOCOMTEGFRCYP2C9MEN1 | |
| SCHEMBL32669656 | 0.80 | FTO (0.49) | FTOCOMTEGFRCYP2C9ALDH1A1 | |
| SCHEMBL32669599 | 0.80 | COMT (0.40) | FTOCOMTCYP2C9MEN1ALDH1A1 | |
| SCHEMBL30740925 | 0.79 | COMT (0.57) | FTOCOMTEGFRCYP2C9MEN1 | |
| SCHEMBL32669799 | 0.76 | FTO (0.43) | FTOCOMTEGFRCYP2C9MEN1 | |
| SCHEMBL32670025 | 0.76 | FTO (0.77) | FTOCOMTCYP2C9MEN1KMT2A | |
| SCHEMBL32669541 | 0.75 | TTR (0.44) | FTOCOMTEGFRKMT2ADHODH | |
| SCHEMBL9653344 | 0.72 | LMNA (0.42) | SMN1; SMN2DHODH | |
| SCHEMBL9653347 | 0.72 | LMNA (0.42) | SMN1; SMN2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | FTO 1/4885COMT 52/4885EGFR 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.